- Home
- DRIO vs BBBYW Comparison
DRIO vs BBBYW Comparison
Compare DRIO & BBBYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DRIO | BBBYW |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.8M | 59.2M |
| IPO Year | 2013 | 2002 |
Fundamental Metrics
Financial Performance| Metric | DRIO | BBBYW |
|---|---|---|
| Price | $6.76 | $0.60 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $35.00 | N/A |
| AVG Volume (30 Days) | 18.0K | ★ 191.6K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1559.02 | 74.64 |
| EPS | ★ 1.75 | N/A |
| Revenue | $7,394,000.00 | ★ $1,044,616,000.00 |
| Revenue This Year | $20.27 | N/A |
| Revenue Next Year | $47.58 | N/A |
| P/E Ratio | $3.99 | ★ N/A |
| Revenue Growth | ★ 43.02 | N/A |
| 52 Week Low | $5.84 | $0.52 |
| 52 Week High | $17.74 | $1.20 |
Technical Indicators
Market Signals| Indicator | DRIO | BBBYW |
|---|---|---|
| Relative Strength Index (RSI) | 48.69 | 52.27 |
| Support Level | $6.18 | N/A |
| Resistance Level | $8.01 | $1.20 |
| Average True Range (ATR) | 0.46 | 0.16 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 46.15 | 21.22 |
Price Performance
Historical ComparisonAbout DRIO DarioHealth Corp.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. The company vertically integrated a health intelligence platform with a mission to power the behavior changes that drive greater health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, and AI built on that proprietary data. The company focuses on delivering user experiences, longer sustained engagement, and stronger clinical outcomes, at affordable prices, which then delivers the highest return on investment in the industry.